Who We Are
What We Do
How We Do It
Where We Do It
Value, Access, and Pricing
A new economic era is dawning, and understanding how value can best support price and access will be essential to the success of future and current brands.
From new modes of administration to new mechanisms of action, specialty therapeutic landscapes are crowding with new dimensions of competition. Understanding local market perceptions and behaviours are just the beginning to developing a sound commercial strategy with the expertise of CBPartners’ team.
As market and payer realities evolve, it will be essential to adapt to meet new stakeholder needs, as well as to understand the value of that adaptation.
Government Policy Advisory
The world’s landscape is quickly evolving due to both innovation and government policy. Ensuring that these policies match political and commercial goals is possible through the expertise of CBPartners’ team.
What’s Next for Alzheimer’s Disease?
09 June 2020
2019 NRDL: Insights for Future Pricing Negotiations in China
2 June 2020
A Summary of CBPartners’ Posters and Workshops from Virtual ISPOR 2020
22 May 2020
Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?
29 April 2020
THE COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe
6 April 2020
Tumor-Agnostic Therapies: The Complex Path to Commercial Viability
24 March 2020
Genome Editing: An Introduction
4 March 2020
View All Blog Posts
ISPOR International: Times That Try Souls
07 July 2017
Cyrus A. Chowdhury
Sandeep Duttagupta, PhD
ISPOR BOSTON: Pharmaceutical Strategic Pricing: An Analysis of Global Cross-SKU Pricing Approaches
ISPOR BOSTON: The Effectiveness of the FDA Priority Review Voucher for Neglected Tropical Diseases and Rare Pediatric Diseases
ISPOR BOSTON: Risk-Sharing Agreements (RSA) in Emerging Markets: Is it a Wake-Up Call or is it Innovation Too Late?
ISPOR BOSTON: How the Purchase and Use of a FDA Priority Review Voucher Affects Product Uptake and Value Conversion
Forecasting Failure: Learning from the Accuracy of Hindsight
ISPOR Asia 2016: Taming Enthusiasm
View All White Papers